Creating a tiny device to analyze cancer cell behavior in leukemia patients
Design of an integrated microdevice to measure malignant lipid signaling in single cells from clinical samples
This study is working on a small device that can look closely at how certain enzymes in individual cancer cells from leukemia patients affect their response to chemotherapy, with the goal of improving treatment options for those with acute myeloid leukemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11123045 on NIH RePORTER |
What this research studies
This research focuses on developing a miniaturized device that can analyze the biochemical activities of lipid-modifying enzymes in single cancer cells from patients with acute myeloid leukemia (AML). By using advanced engineering techniques, the project aims to create a highly sensitive and efficient tool called picoliter thin-layer chromatography (pTLC) that can be used in clinical settings. The device will allow for high-throughput analysis, helping to understand how certain enzymes contribute to chemotherapy resistance in leukemia patients. This innovative approach combines bioengineering, chemistry, and oncology to improve patient care and treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, including both children and adults.
Not a fit: Patients with other types of leukemia or those not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and treatment strategies for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in using miniaturized analytical devices for cancer analysis, indicating potential success for this novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Allbritton, Nancy L. — University of Washington
- Study coordinator: Allbritton, Nancy L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.